Getting paid to buy Novo Nordisk: earn income while waiting for a better price

Getting paid to buy Novo Nordisk: earn income while waiting for a better price

Options 10 minutes to read
MicrosoftTeams-image (3)
Koen Hoorelbeke

Investment and Options Strategist

Getting paid to buy Novo Nordisk: earn income while waiting for a better price

After a spectacular run-up through 2023 and early 2024, Novo Nordisk shares have cooled down. The stock, once the poster child of the GLP-1 obesity drug boom, now trades around USD 69—down sharply from its highs near USD 135. A recent combination of supply bottlenecks, executive changes, and a slightly more cautious outlook has added volatility to the share price. But for long-term investors who still believe in Novo’s story, that volatility opens a door.

What if you could get paid while waiting to buy the shares at a discount?

That’s exactly what a cash-secured put strategy offers.


A look at Novo’s journey—and the current pull-back

Over the last five years, Novo Nordisk has delivered stellar returns, fueled by global demand for its diabetes and weight-loss medications, particularly Ozempic and Wegovy. But every great growth story experiences pauses. As you can see in the chart below, the recent correction has brought the stock back to levels last seen in late 2023.

2025-07-08-00-NVO-CSP-5y-chart
Five-year stock price chart of Novo Nordisk showing steady growth until late 2024, followed by a pull-back © Saxo

We’re using the U.S.-listed ADR version of Novo Nordisk (ticker: NVO) because options are not available on the Denmark-listed shares.

This retracement doesn’t necessarily mean the story is over—it may simply mean the valuation got ahead of itself. And if you’re a long-term investor who believes in the future of GLP-1 treatments, the current price may feel like an opportunity.

But instead of buying shares outright at  USD 69, there’s a more strategic approach.

Important note: The strategies and examples described are purely for educational purposes. They assist in shaping your thought process and should not be replicated or implemented without careful consideration. Every investor must conduct their own due diligence, considering their financial situation, risk tolerance, and investment objectives before making decisions. Remember, investing in the stock market carries risks, so make informed decisions.


What’s a cash-secured put, in plain English?

Imagine you’re willing to buy 100 Novo shares—but only if the price drops a little more, say to USD 64. Now imagine someone pays you  USD 170 today for that possibility. That’s a cash-secured put: you’re selling someone else the right to sell you shares at a set price, and in return, you’re paid a premium upfront.

To do this safely, you set aside the full amount needed to buy the shares (USD 6 400 in this case), so you’re covered if it happens. It’s called “cash-secured” because your obligation is fully backed by cash.

This strategy is particularly suitable for conservative investors. You either:

  • Earn income if the shares stay above your target price, or
  • Buy the stock you already wanted, but at a discount.

Let’s look at a real example.


The trade: selling the USD 64 put expiring August 8, 2025

As of today, with Novo Nordisk trading near USD 69, the August 8 put option with a USD 64 strike is trading around USD 1.70 per share. That means you can collect USD 170 in premium (since each contract represents 100 shares) for agreeing to buy the stock at USD 64 if it drops.

2025-07-08-00-NVO-CSP-option-chain
Option chain for Novo Nordisk showing the $64 strike put expiring August 8, 2025 with a bid-ask of 1.58–1.74 © Saxo

To execute this, you'd sell one put contract and set aside USD 6 400 in cash. That’s the maximum you’d need to buy the shares if assigned.

Now here’s the part that many investors love: if the share price stays above USD 64 through August 8, the put expires worthless—and you keep the USD 170 premium. On a cash commitment of USD 6 400, that’s a 2.7% return in just 32 days.

On an annualised basis, that works out to roughly 29%, assuming you could repeat this kind of trade every month (which, of course, isn’t guaranteed).

2025-07-08-01-NVO-CSP-strategy
Strategy window showing a short put position on Novo Nordisk with a $64 strike and $170 premium, including risk-reward graph. © Saxo

This “get paid to wait” yield is the real power of cash-secured puts—especially when premiums are elevated, as they are now due to increased short-term volatility in the stock.


What can happen at expiration?

There are two possible outcomes—both acceptable, depending on your investment goals.

Scenario 1: Novo stays above USD 64
Your put expires worthless. You keep the $170 premium as pure income. Your €6 400 in cash was never used to buy shares, and you can now consider repeating the strategy for another month.

Scenario 2: Novo falls below USD 64
You’re assigned 100 shares at USD 64, which you already agreed to. But thanks to the USD 1.70 premium you received, your effective purchase price is USD 62.30—a further 10% discount from where the stock was trading just a few weeks ago. From here, you could simply hold the shares or start generating income with a covered call.


Risks to keep in mind

No investment strategy is without risk—even one that sounds this conservative.

The biggest risk here is that Novo drops well below USD 64 before expiration. If the stock falls to USD 55, for instance, you’d still be obligated to buy it at USD 64, meaning you'd have a paper loss on your new position. However, because you were paid USD 1.70 upfront, your break-even point is actually USD 62.30.

Another factor to be aware of: Novo Nordisk trades as an ADR on the NYSE (ticker: NVO), but its home listing is in Denmark. That means movements in the Danish krone (DKK) versus the US dollar can also influence the price. And like all pharma stocks, headlines about clinical trials, competition (such as Eli Lilly’s Zepbound), or regulatory changes can move the share price quickly.


Final thoughts

If you're a long-term investor looking to add Novo Nordisk to your portfolio, selling a cash-secured put at $64 offers a compelling way to do so—either collecting a ~2.7% yield in one month or buying the stock nearly 10% below the current price.

It’s a calm, measured approach in a market that’s been anything but.

Just remember: while cash-secured puts are straightforward, they still require a clear plan. Know how much capital you’re willing to commit, stick to high-quality names you’re happy to own, and never forget that your real return depends on both outcome and discipline.

This material is marketing content and should not be regarded as investment advice. Trading financial instruments carries risks and historic performance is not a guarantee of future results.
The instrument(s) referenced in this content may be issued by a partner, from whom Saxo receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options..

Quarterly Outlook

01 /

  • Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Quarterly Outlook

    Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    Quarterly Outlook

    Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    John J. Hardy

    Global Head of Macro Strategy

    After the chaos of Q2, the quarter ahead should get a bit more clarity on how Trump 2.0 is impacting...
  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.